Results 161 to 170 of about 5,339,936 (244)

Tissue‐Resident Macrophage in Inflammation and Cancer

MedComm, Volume 7, Issue 9, September 2026.
Opposing macrophage functions in inflammation and cancer converge on shared mechanistic nodes, informing cross‐disease therapeutic strategies. ABSTRACT Tissue‐resident macrophages (TRMs) are long‐lived immune cells strategically distributed across organs, where their functional plasticity enables both homeostatic maintenance and pathological ...
Siyuan Huang, Jiangbo Fan, Wenyi Liu, Di Liu, Rui Wang, Yuanyang Wang, Jianhui Sun, Huacai Zhang, Qingli Cai, Zhe Xu, Fang Xu, Jianxin Jiang, Zhen Wang, Ling Zeng   +13 more
wiley   +1 more source

Circulating tumor cells (CTCs) – clinical significance in patients with ovarian cancer [PDF]

, 1970
Circulating tumor cells (CTCs) are cells released from the primary tumor and circulating in peripheral blood. CTCs are an important element in the process of understanding the biology of metastases.
Bochyński, Hubert, Spaczyński, Marek, Magnowski, Piotr, Nowak-Markwitz, Ewa, Zabel, Maciej   +4 more
core  

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Bone scan index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastases. [PDF]

Sci Rep, 2023
Hirano H, Nagata M, Nagaya N, Nakamura S, Ashizawa T, Lu Y, Kawano H, Kitamura K, Sakamoto Y, Fujita K, Isobe H, Tsujimura A, Muto S, Horie S.   +13 more
europepmc   +1 more source

Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: a prospective cohort study based on ISET device

, 2018
Chaogang Yang,1–3,* Dongdong Shi,1–3,* Shuyi Wang,1–3 Chen Wei,1–3 Chunxiao Zhang,1–3 Bin Xiong1–3 1Department of Gastrointestinal Surgery and Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital ...
Wang S, Wei C, Xiong B, Shi D, Zhang C, Yang C   +5 more
core  

TLR7 Agonist Nanomedicine Suppresses Lung Metastasis of Osteosarcoma by Remodeling the Immune Microenvironment

MedComm – Oncology, Volume 5, Issue 3, September 2026.
In tail‐vein and orthotopic osteosarcoma mouse models, 1V209‑Cho‑Lip, a TLR7 agonist liposome, effectively suppresses pulmonary metastasis and prolongs survival. Flow cytometry and single‑cell transcriptomics reveal that 1V209‑Cho‑Lip remodels both the pre‑metastatic and post‑metastatic immune microenvironments, alleviates myeloid‑mediated ...
Xinyue Zhang, Hao Zeng, Furong Qin, Yuquan Wei, Dandan Wan, Xiawei Wei   +5 more
wiley   +1 more source

PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). [PDF]

Biomedicines, 2022
Pantazaka E, Ntzifa A, Roumeliotou A, Lianidou E, Georgoulias V, Kotsakis A, Kallergi G.   +6 more
europepmc   +1 more source

The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Non-muscle invasive bladder cancer (NMIBC) presents substantial variability in clinical outcomes, especially in high-grade T1 cases, which exhibit high recurrence and progression rates. Circulating tumor cells (CTCs) have emerged as a potential biomarker
Belinda Liliana, Nurul Lantika Mataho, Andy Zulfiqqar, Eko Subekti   +3 more
core   +1 more source

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, Volume 15, Issue 3, Page 164-175, September 2026.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, Volume 15, Issue 3, Page 206-226, September 2026.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source